查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961288

多西他賽三水合物原料藥市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、應用、最終用戶、地區和競爭對手分類，2021-2031年

Docetaxel Trihydrate API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球多西他賽三水合物活性原料藥市場預計將從 2025 年的 14.5 億美元成長到 2031 年的 21.1 億美元，複合年成長率為 6.45%。

該藥物的活性成分是一種紫杉烷抗腫瘤藥物，用於胃癌、前列腺癌、非小細胞肺癌和乳癌的化療。它作為微管抑制劑，穩定細胞骨架，從而阻止細胞分裂並誘導細胞凋亡。市場成長的主要驅動力是全球癌症發生率的上升以及對有效治療方法的需求。同時，原廠藥專利到期促進了價格低廉的學名藥的生產，從而增加了對這種重要化合物的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 14.5億美元
市場規模：2031年 21.1億美元
複合年成長率：2026-2031年 6.45%
成長最快的細分市場 製藥公司
最大的市場 北美洲

儘管需求強勁，但市場仍面臨許多挑戰，包括供應鏈可靠性以及高活性化合物生產流程的複雜性，這些都可能導致產品短缺和供應不穩定。根據美國醫療保健系統藥劑師協會 (ASHP) 的數據，2024 年醫療保健行業出現了創紀錄的 323 種藥品短缺，其中多西他賽等關鍵無菌注射劑受到衝擊。這些供應中斷凸顯了供應鏈網路的脆弱性，並對全球市場的穩定擴張構成重大障礙。

市場促進因素

多西他賽三水合物原料藥市場的主要驅動力是全球目標癌症發生率的不斷上升，包括乳癌、攝護腺癌和非小細胞肺癌。這導致對成熟化療藥物的需求增加。長期流行病學預測也支持這一成長趨勢。世界衛生組織（WHO）在其2024年2月發布的題為《全球癌症負擔》的新聞稿中指出，預計到2050年，全球新增癌症病例將超過3500萬例，比2022年成長77%。在以多西他賽為標準治療方案的適應症中，這趨勢尤其顯著。例如，美國癌症協會估計，2024年美國將新增310,720例侵襲性乳癌病例，凸顯了該原料藥物在一線和輔助性治療中的持續需求。

此外，各國政府為改善癌症治療的可及性所做的努力正在重塑市場格局，其途徑是解決高活性化合物供應的薄弱環節。監管機構正在實施戰略框架，並促進與生產商的合作，以識別供應瓶頸並實現生產能力多元化，從而應對持續存在的供不應求。一個值得關注的例子是歐盟委員會於2024年4月啟動的「重要藥物聯盟」。該聯盟匯集了約250個成員組織，旨在加強供應鏈並防止供不應求，為原料藥生產商創造更穩定的環境，並確保患者能夠獲得挽救生命的治療。

市場挑戰

多西他賽三水合物原料藥市場成長的主要障礙在於供應鏈的脆弱性和高活性藥物原料藥生產相關的技術複雜性。這種紫杉烷類化合物的生產需要專門的密閉設施和嚴格的品管。這些要求限制了能夠生產該產品的製造商數量，從而造成供應瓶頸。因此，當物流中斷影響到這個脆弱的供應鏈網路時，製造商無法迅速擴大生產規模以滿足不斷成長的全球需求，導致收入損失，並阻礙市場充分利用癌症發病率上升所帶來的機會。

這些供應鏈功能障礙的影響十分嚴重，2024年美國國家綜合癌症網路（NCCN）的調查結果就印證了這一點。 89%的受訪癌症中心報告稱，關鍵抗癌藥物和輔助治療藥物出現短缺。這種普遍的供不應求迫使醫療機構限制劑量或將患者轉為替代療法，導致多西他賽的即時消耗量下降。最終，產品供應的持續不穩定正在破壞市場穩定，並顯著減緩這種關鍵原料藥的商業性擴張。

市場趨勢

奈米技術藥物遞送系統的發展正在改變市場格局，這主要得益於製造商為降低傳統溶劑型製劑的毒性所做的努力。諸如白蛋白結合型多西他賽奈米顆粒等創新技術因其無需預先使用皮質類固醇並能減少超敏反應而備受關注，而監管區域的戰略許可協議進一步推動了這一趨勢。例如，Zydus Life Sciences 在 2025 年 2 月發布的新聞稿《Zydus Life Sciences 獲得美國抗癌藥物許可》中宣布，美國對多西他賽注射劑的年商業性預計將達到約 53.1 萬支，這體現了這些改良產品的商業潛力。

同時，抗體藥物複合體（ADC）細胞毒性有效載荷生產過程的日益複雜化，正推動高活性藥物原料藥（HPAPI）的生產外包給專業的契約製造生產商。製藥公司越來越傾向於利用專業化、高防護等級的合約研發生產機構（CDMO），而不是自建資本密集設施，這刺激了對生產能力的顯著投資。例如，2025年6月，Piramal Pharma Solutions宣布投資9,000萬美元擴建其美國原料藥，旨在增強其HPAPI和ADC有效載荷連接子的商業化生產能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球多西他賽三水合物原料藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（純度 99% 或更高，純度低於 99%）
    • 依應用領域（腫瘤學、研發、其他）
    • 依最終用戶（製藥公司、研究機構、契約製造組織）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：多西他賽三水合物原料藥北美市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲多西他賽三水合物原料藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區多西他賽三水合物原料藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東及非洲多西他賽三水合物原料藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美多西他賽三水合物原料藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球多西他賽三水合物原料藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc
  • Accord Healthcare, Inc
  • Sandoz Group AG
  • Aurobindo Pharma Ltd Inc
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27653

The Global Docetaxel Trihydrate API Market is projected to expand from USD 1.45 Billion in 2025 to USD 2.11 Billion by 2031, registering a CAGR of 6.45%. This active pharmaceutical ingredient is a taxane-derived antineoplastic agent used in chemotherapy for gastric, prostate, non-small cell lung, and breast cancers, acting as a microtubule inhibitor that stabilizes the cellular cytoskeleton to halt cell division and trigger apoptosis. Market growth is largely driven by the increasing global prevalence of cancer and the need for effective therapeutic regimens, while the expiration of innovator patents has boosted the production of affordable generics and increased the volume requirements for this essential compound.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.45 Billion
Market Size 2031USD 2.11 Billion
CAGR 2026-20316.45%
Fastest Growing SegmentPharmaceutical Companies
Largest MarketNorth America

Despite strong demand, the market faces significant hurdles regarding supply chain reliability and the complexities involved in manufacturing high-potency compounds, which often lead to product scarcity and inconsistent availability. Data from the American Society of Health-System Pharmacists indicates that the healthcare sector experienced a record 323 active drug shortages in 2024, affecting critical sterile injectables like docetaxel. These interruptions demonstrate the vulnerability of the supply network and pose a major obstacle to the steady expansion of the global market.

Market Driver

The primary driver for the Docetaxel Trihydrate API market is the escalating global incidence of target cancer indications, including breast, prostate, and non-small cell lung malignancies, which necessitates higher production volumes of established chemotherapeutic agents. Long-term epidemiological projections confirm this surge, with the World Health Organization reporting in a February 2024 press release titled 'Global cancer burden growing' that over 35 million new cancer cases are anticipated in 2050, marking a 77% rise from 2022 levels. This trend is especially pronounced in indications where docetaxel is a standard treatment; for example, the American Cancer Society estimated that 310,720 new invasive breast cancer cases would be diagnosed in the United States in 2024, highlighting the enduring need for this API in first-line and adjuvant therapies.

Additionally, government initiatives aimed at improving access to cancer treatments are reshaping the market by targeting vulnerabilities in the supply of high-potency compounds. Regulatory authorities are implementing strategic frameworks and fostering collaboration with manufacturers to identify supply constraints and diversify production capabilities in response to persistent shortages. A notable instance is the European Commission's launch of the Critical Medicines Alliance in April 2024, which convened approximately 250 members to reinforce the supply chain and prevent scarcity, thereby creating a more stable environment for API producers and ensuring patient access to life-saving therapies.

Market Challenge

A major impediment to the growth of the Docetaxel Trihydrate API market is the combination of supply chain vulnerabilities and the technical complexity involved in manufacturing high-potency active pharmaceutical ingredients. The production of this taxane-derived compound demands specialized containment facilities and strict quality controls, requirements that limit the number of capable manufacturers and create supply bottlenecks. Consequently, when logistical disruptions impact this fragile network, manufacturers are unable to rapidly scale production to meet rising global demand, leading to revenue losses and preventing the market from fully capitalizing on increasing cancer rates.

The consequences of these supply chain failures are severe, as evidenced by the National Comprehensive Cancer Network's 2024 findings, where 89% of surveyed cancer centers reported shortages of key anti-cancer agents and supportive medications. Such widespread scarcity compels medical providers to ration doses or switch patients to alternative treatments, effectively lowering the immediate consumption of docetaxel formulations. Ultimately, the persistent unreliability of product availability destabilizes the market and significantly slows the commercial expansion of this critical API.

Market Trends

The market is being transformed by the development of nanotechnology-based drug delivery systems, as manufacturers strive to reduce the toxicity linked to traditional solvent-based formulations. Innovations such as albumin-bound docetaxel nanoparticles are becoming popular for their ability to eliminate the need for corticosteroid premedication and lower hypersensitivity reactions, a trend supported by strategic licensing agreements in regulated regions. Highlighting the commercial potential of these improved profiles, Zydus Lifesciences noted in a February 2025 press release titled 'Zydus Lifesciences Licenses Cancer Drug in US' that the US market for docetaxel injection sees an annual volume uptake of roughly 531,000 units.

Concurrently, there is a shift toward outsourcing to specialized High Potency Active Pharmaceutical Ingredient (HPAPI) contract manufacturers due to the growing complexity of producing cytotoxic payloads for antibody-drug conjugates (ADCs). Pharmaceutical innovators are increasingly utilizing Contract Development and Manufacturing Organizations (CDMOs) with niche high-containment infrastructure rather than investing in their own capital-intensive facilities, prompting significant investment in manufacturing capacity. For example, Piramal Pharma Solutions announced a $90 million investment in June 2025 to expand its US facilities, specifically aimed at enhancing commercial-scale capabilities for high-potency APIs and ADC payload-linkers.

Key Market Players

  • Pfizer Inc
  • Accord Healthcare, Inc
  • Sandoz Group AG
  • Aurobindo Pharma Ltd Inc
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

Report Scope

In this report, the Global Docetaxel Trihydrate API Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Docetaxel Trihydrate API Market, By Product Type

  • Purity >= 99%
  • Purity < 99%

Docetaxel Trihydrate API Market, By Application

  • Oncology
  • Research and Development
  • Others

Docetaxel Trihydrate API Market, By End-User

  • Pharmaceutical Companies
  • Research Institutes
  • Contract Manufacturing Organizations

Docetaxel Trihydrate API Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Docetaxel Trihydrate API Market.

Available Customizations:

Global Docetaxel Trihydrate API Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Docetaxel Trihydrate API Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Purity >= 99%, Purity < 99%)
    • 5.2.2. By Application (Oncology, Research and Development, Others)
    • 5.2.3. By End-User (Pharmaceutical Companies, Research Institutes, Contract Manufacturing Organizations)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Docetaxel Trihydrate API Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Docetaxel Trihydrate API Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Docetaxel Trihydrate API Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Docetaxel Trihydrate API Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Docetaxel Trihydrate API Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Docetaxel Trihydrate API Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Docetaxel Trihydrate API Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Docetaxel Trihydrate API Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Docetaxel Trihydrate API Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Docetaxel Trihydrate API Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia Pacific Docetaxel Trihydrate API Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Docetaxel Trihydrate API Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Docetaxel Trihydrate API Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Docetaxel Trihydrate API Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Docetaxel Trihydrate API Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Docetaxel Trihydrate API Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Docetaxel Trihydrate API Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Docetaxel Trihydrate API Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Docetaxel Trihydrate API Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Docetaxel Trihydrate API Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. South America Docetaxel Trihydrate API Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Docetaxel Trihydrate API Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Docetaxel Trihydrate API Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Docetaxel Trihydrate API Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Docetaxel Trihydrate API Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Accord Healthcare, Inc
  • 15.3. Sandoz Group AG
  • 15.4. Aurobindo Pharma Ltd Inc
  • 15.5. Cipla Inc.
  • 15.6. Hikma Pharmaceuticals PLC
  • 15.7. Sun Pharmaceutical Industries Ltd.
  • 15.8. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer